2025-01-31 11:37:00 :
Ajanta Pharmaceuticals Q3 Result 2025: Ajanta Pharmaceuticals announced on January 30, 2025 that the results of its third quarter, the report increased by 3.71 % year -on -year. The profit has soared 10.88 %, in total Bleak232.88 million, and the income reached Bleak1146.13 million. However, compared with the previous quarter, revenue decreased by 3.41 %, although the profit increased by 7.58 %.
The company’s sales generally increased by 1.61 % of the administrative expenses of 1.61 %, an increase of 14.62 % year -on -year, which reflects the rise in operating costs.
In terms of operating income, a quarter of the economic recession decreased by 5.81 %, a year -on -year decrease of 0.88 %. In the third quarter of the income (EPS), standing Bleak18.59 reflects the growth of 11.52 %, which indicates that the growth of profitability indicators is growing.
Ajanta Pharmaceuticals recently faced a challenging market. The return rate last week was -7.57 %. The return rate of the past six months was -4.14 %, and the return -8.71 %.
As of January 31, 2025, the market value of Ajanta Pharmaceuticals stood on the market value Bleak33,437.509 million, 52 weeks high Bleak3485 and low Bleak1998.35.
Analyst’s emotions are mixed. As of January 31, 2025, 9 analysts have covered the company. Among these analysts, two analysts rated it as a strong selling, one sold, three as a buy, and three as a strong buy. The current consensus suggestion is to buy, indicating that the company’s future performance is optimistic.
Ajanta Pharmaceuticals Financials
period | Q3 (FY25) | Q2 (FY25) | QOQ growth | Q3 (FY24) | Annual growth |
---|---|---|---|---|---|
Total income | 1146.13 | 1186.64 | -3.41 % | 1105.15 | +3.71 % |
Sales/general/management costs total | 265.17 | 260.96 | +1.61 % | 231.35 | +14.62 % |
Depreciation/amortization | 35.97 | 34.39 | +4.59 % | 34.26 | +4.99 % |
Total operating expenses | 861.27 | 884.21 | -2.59 % | 817.76 | +5.32 % |
Operating income | 284.86 | 302.43 | -5.81 % | 287.39 | -0.88 % |
Net income before tax | 307.39 | 290.24 | +5.91 % | 290.91 | +5.66 % |
net income | 232.88 | 216.48 | +7.58 % | 210.03 | +10.88 % |
Diluted normalization EPS | 18.59 | 17.26 | +7.71 % | 16.67 | +11.52 % |
Disclaimer: This is a live blog generated by AI, which has not been edited by Livemint employeesEssence
Follow us On Social Media Twitter/X